A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Adalimumab (GP2017) and Humira in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Trial Profile

A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Adalimumab (GP2017) and Humira in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms ADACCESS
  • Sponsors HEXAL; Novartis; Sandoz
  • Most Recent Events

    • 14 Nov 2017 Results from this trial were presented at the American College of Rheumatology (ACR) Annual Meeting according to a Sandoz media release.
    • 14 Sep 2017 Results published in a Sandoz Media Release.
    • 14 Sep 2017 According to a Sandoz media release, results from this study were presented at the 26th Congress of the European Academy of Dermatology and Venereology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top